Aarvik Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$2M
- Investors
-
1
Aarvik Therapeutics General Information
Description
Operator of a proprietary modular platform intended to develop site-specific antibody-drug conjugation technology. The company tool is being used to generate a pipeline of proprietary multi-functional ADCs that engage multiple epitopes/targets to result in effective treatments where previous-generation ADCs failed or were sub-optimal and develop novel molecules with an improved therapeutic index for oncology targets, enabling biotechnology companies to create transformational benefits for cancer patients.
Contact Information
Website
www.aarviktx.comCorporate Office
- 31363 Medallion Drive
- Hayward, CA 94544
- United States
Corporate Office
- 31363 Medallion Drive
- Hayward, CA 94544
- United States
Aarvik Therapeutics Timeline
Aarvik Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 29-Sep-2025 | $2M | Completed | Generating Revenue | ||
| 2. Early Stage VC (Series A) | 10-Dec-2024 | Completed | Generating Revenue | |||
| 1. Seed Round | 02-Sep-2021 | $8.32M | $8.32M | Completed | Generating Revenue |
Aarvik Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Aarvik Therapeutics Patents
Aarvik Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026232141-A1 | B7h3/trop2 antibodies and methods of use | Pending | 02-May-2025 | ||
| WO-2026183370-A2 | B7h3/epha2 antibodies and methods of use | Pending | 27-Feb-2025 | ||
| WO-2026183370-A3 | B7h3/epha2 antibodies and methods of use | Pending | 27-Feb-2025 | ||
| US-20260256939-A1 | Fluorocamptothecin compounds, conjugates, and methods thereof | Pending | 07-May-2024 | ||
| WO-2025235686-A1 | Fluorocamptothecin compounds, conjugates, and methods thereof | Pending | 07-May-2024 | A61K47/68037 |
Aarvik Therapeutics Signals
Aarvik Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Laurus Labs | Corporation | Minority |
Aarvik Therapeutics FAQs
-
When was Aarvik Therapeutics founded?
Aarvik Therapeutics was founded in 2020.
-
Where is Aarvik Therapeutics headquartered?
Aarvik Therapeutics is headquartered in Hayward, CA.
-
What is the size of Aarvik Therapeutics?
Aarvik Therapeutics has 11 total employees.
-
What industry is Aarvik Therapeutics in?
Aarvik Therapeutics’s primary industry is Drug Discovery.
-
Is Aarvik Therapeutics a private or public company?
Aarvik Therapeutics is a Private company.
-
What is Aarvik Therapeutics’s current revenue?
The current revenue for Aarvik Therapeutics is .
-
How much funding has Aarvik Therapeutics raised over time?
Aarvik Therapeutics has raised $11.5M.
-
Who are Aarvik Therapeutics’s investors?
Laurus Labs has invested in Aarvik Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process